ANVS

Maxim Group analyst Jason McCarthy maintained a Buy rating on Annovis Bio (ANVS - Research Report) yesterday and set a price target of $26.00. The company's shares opened today at $11.50.According to TipRanks, McCarthy is an analyst with an average return of -37.1% and a 16.40% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Plus Therapeutics, Atossa Therapeutics, and Capricor Therapeutics.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Annovis Bio with a $26.00 average price target.
https://www.tipranks.com/news/blurbs/annovis-bio-anvs-gets-a-buy-from-maxim-group?utm_source=advfn.com&utm_medium=referral